CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · Real-Time Price · USD
1.975
-0.005 (-0.25%)
At close: Nov 14, 2025, 4:00 PM EST
1.810
-0.165 (-8.35%)
After-hours: Nov 14, 2025, 5:10 PM EST
CollPlant Biotechnologies Revenue
CollPlant Biotechnologies had revenue of $179.00K in the quarter ending June 30, 2025, a decrease of -28.11%. This brings the company's revenue in the last twelve months to $2.40M, up 248.62% year-over-year. In the year 2024, CollPlant Biotechnologies had annual revenue of $515.00K, down -95.30%.
Revenue (ttm)
$2.40M
Revenue Growth
+248.62%
P/S Ratio
9.50
Revenue / Employee
$42,140
Employees
57
Market Cap
25.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 515.00K | -10.44M | -95.30% |
| Dec 31, 2023 | 10.96M | 10.66M | 3,565.22% |
| Dec 31, 2022 | 299.00K | -15.34M | -98.09% |
| Dec 31, 2021 | 15.64M | 9.50M | 154.86% |
| Dec 31, 2020 | 6.14M | 3.82M | 164.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CLGN News
- 20 days ago - CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada - PRNewsWire
- 27 days ago - CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology - PRNewsWire
- 4 weeks ago - First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk - PRNewsWire
- 6 weeks ago - CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler - PRNewsWire
- 2 months ago - CollPlant Expands the Distribution of its VergenixSTR Product in Europe - PRNewsWire
- 2 months ago - CollPlant to Present at the 2025 International Conference on Biofabrication - PRNewsWire
- 2 months ago - CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference - PRNewsWire
- 3 months ago - COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PRNewsWire